trial
as of 2026-07-01Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
NCTId NCT04127058
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2019-11-27
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2019-10-07
Primary completion
2019-11-27
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
1 total
Marlton, United States
Facts & assertions
4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2019-11-27
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication